A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is part of the Institut Mérieux group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.
Find locations served, office locations
- Business Type:
- Industry Type:
- Health Care
- Market Focus:
- Globally (various continents)
- Year Founded:
- more than 1,000,000,000 €
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
In 2013, bioMérieux celebrated a major milestone, our 50th anniversary. Our development during these years has been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 41 subsidiaries and a large network of distributors, bioMérieux provides diagnostic solutions that improve patient health and ensure consumer safety.
We develop tests that bring high medical value for clinical decisions in the areas of infectious diseases, cardiovascular emergencies and targeted cancers. In industrial applications, we contribute to preventing contamination risks in agri-food, pharmaceutical and cosmetic products.
We also bring progress to laboratories: by increasing automation and improving data management, we are helping to reinforce the efficiency of healthcare structures, increase lab productivity, and reduce healthcare costs.
bioMérieux is determined to continue to play a pioneering role by innovating and designing the diagnostics of the future to address the major challenges for public health worldwide.
bioMérieux’s commitment to public health and expertise in biology are rooted in its unique family history. In 1897, Marcel Mérieux, a student of Louis Pasteur, founded an analysis laboratory in Lyon that would become Institut Mérieux. This marks the start of an extraordinary adventure in both biology and industry.
In 1937, his son, Dr Charles Mérieux, took up the reins of his father’s laboratory. In the 1940’s, he introduced a technique developed by the Dutch Professor Frenkel - in vitro culture – which revolutionized the manufacture of vaccines and led to the production of reagents for in vitro diagnostic testing.
In 1963, Alain Mérieux, grandson of Marcel, established the diagnostics company, bioMérieux. Today it is part of Institut Mérieux, whose companies in diagnostics, immunotherapy, food safety and nutrition, are working to meet the new challenges in public health and contribute to the medicine of tomorrow.
50 years of Friendshiptop
On March 26, 2014 during a state visit to France commemorating the 50th anniversary of diplomatic relations between France and China, President Xi Jinping, accompanied by the First Lady of China and an official delegation, honored the bioMérieux headquarters at Marcy l'Étoile with a visit.
- Improving patient health through a complete range of in vitro diagnostic solutions for the management of:
- infectious diseases,
- cardiovascular diseases,
- targeted cancers.
- Improving laboratory operational efficiency.
- Ensuring consumer safety and product quality with solutions for detecting microorganisms to track and prevent product contaminations:
- food ;
3 Areas of Focus
- Medical and technological innovation.
- Geographical expansion.
- Targeted acquisitions and partnerships.
4 Ambitious Objectives
- Extend our leadership in clinical and industrial microbiology.
- Maximize our position in immunoassays.
- Grow our molecular biology business.
- Pursue our international development, primarily in emerging countries and North America.